Seeking Alpha

Shares of biotech researcher ArQule (ARQL +4%) advanced after Needham initiates coverage with a...

Shares of biotech researcher ArQule (ARQL +4%) advanced after Needham initiates coverage with a Buy and an $11 price target. The firm cites the development potential of its lung cancer drug, tivantinib, and recommends scooping up shares ahead of "multiple value-creating data milestones" expected over the next year.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)